Skip to main content

STAAR Surgical Company

corporate_fare Company Profile

STAAR Surgical Company

STAA·NASDAQ·Industrial Applications And Services·CIK 0000718937

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems. The company is a leading manufacturer of phakic implantable lenses used globally in corrective or "refractive" surgery, with over 40 years dedicated to ophthalmic surgery. STAAR generates worldwide revenue almost exclusively from sales of its Implantable Collamer Lenses, or "ICLs." These ICLs are made from Collamer, a proprietary collagen copolymer material created and exclusively used by STAAR, making the lenses soft, flexible, and biocompatible with the eye. ICLs are phakic lenses, implanted into the eye without removing the natural crystalline lens, distinguishing them from other refractive procedures that involve corneal tissue removal. All ICLs are foldable, allowing for insertion through a small incision during minimally invasive surgery. While intended to be permanent, STAAR's ICLs are reversible lens implants. The company markets and sells its "EVO" family of lenses for refractive surgery to treat myopia (nearsightedness), which includes the EVO ICL, EVO+ ICL, and EVO Visian ICL. The newest offering, EVO Viva, features an extended depth of focus (EDoF) optic designed to treat myopia with presbyopia (age-related loss of ability to focus). STAAR also markets and sells an ICL lens called Visian ICL to treat hyperopia (farsightedness).

STAAR Surgical Company (NASDAQ:STAA) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 29 items for STAA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • STAAR Surgical Appoints President Foust and CFO Andrews as Interim Co-CEOs
  • Activist Broadwood Partners Secures Board Seats, CEO Departure at STAAR Surgical
  • STAAR Surgical Appoints Significant Shareholder Representative to Board
  • STAAR Surgical Appoints Largest Shareholder's Founder as Board Chair, Initiates CEO Search
  • STAAR Surgical CEO Steps Down, Board Overhauled Following Broadwood Partners Agreement

Financial Snapshot

Fiscal year ended January 2, 2026
Revenue
$239.44M
Net Income
-$80.45M
Diluted EPS
-$1.62
Op. Cash Flow
-$34.23M
Free Cash Flow
-$40.05M
Gross Profit
$182.42M
Operating Income
-$91.71M
Cash & Equivalents
$153.15M
Debt / Equity
0.00×
Net Margin
-33.6%
Shares Outstanding
49.4M sh
Source: 10-K · filed 2026-03-03 · accession 0000718937-26-000004
$24.22
52-week range · as of 2026-11-04 $15.59 – $35.87
Market cap
$1.22B
Volume
585.6K (0.8× avg)
3-mo avg 708.8K
Live data · 2026-11-22 00:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed STAA - Filings & News (Page 2)

STAA
Feb 02, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.10
Real-time Price: $24.22 info
Change: +$5.12 (+27%) info
Market Cap: $1.216B info
STAA
Jan 16, 2026, 8:27 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $20.70
Real-time Price: $24.22 info
Change: +$3.52 (+17%) info
Market Cap: $1.216B info
STAA
Jan 16, 2026, 8:03 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $20.70
Real-time Price: $24.22 info
Change: +$3.52 (+17%) info
Market Cap: $1.216B info
STAA
Jan 16, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.06
Real-time Price: $24.22 info
Change: +$3.16 (+15%) info
Market Cap: $1.216B info
STAA
Jan 15, 2026, 9:22 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.54
Real-time Price: $24.22 info
Change: +$2.68 (+12%) info
Market Cap: $1.216B info
STAA
Jan 08, 2026, 7:31 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $22.50
Real-time Price: $24.22 info
Change: +$1.72 (+8%) info
Market Cap: $1.216B info
STAA
Jan 08, 2026, 1:05 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $24.22 info
Change: +$1.62 (+7%) info
Market Cap: $1.216B info
STAA
Jan 06, 2026, 4:54 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.00
Real-time Price: $24.22 info
Change: +$2.22 (+10%) info
Market Cap: $1.216B info
STAA
Jan 06, 2026, 9:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.45
Real-time Price: $24.22 info
Change: +$4.77 (+25%) info
Market Cap: $1.216B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets